Optimal Interval Between Immune Therapy and Targeted Therapy with Sotorasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer
07:30am - 03:45pm EST - March 31, 2023
07:30am - 03:45pm EST - March 31, 2023
Author(s):
- Julia Bielanin, BS, BA, Medical Student, Vanderbilt-Ingram Cancer Center
Tags: Member Institution Clinical Oncology
| Display Label | Action |
|---|---|
| AC23P48 - Optimal Interval Between Immune Therapy and Targeted Therapy with Sotorasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer | Download MP3 |
| 048-General Poster Session | Download Handout |